JP2020510619A5 - - Google Patents

Download PDF

Info

Publication number
JP2020510619A5
JP2020510619A5 JP2019529625A JP2019529625A JP2020510619A5 JP 2020510619 A5 JP2020510619 A5 JP 2020510619A5 JP 2019529625 A JP2019529625 A JP 2019529625A JP 2019529625 A JP2019529625 A JP 2019529625A JP 2020510619 A5 JP2020510619 A5 JP 2020510619A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
sealed container
aqueous pharmaceutical
container according
packaged
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019529625A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020510619A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/066652 external-priority patent/WO2018112330A1/en
Publication of JP2020510619A publication Critical patent/JP2020510619A/ja
Publication of JP2020510619A5 publication Critical patent/JP2020510619A5/ja
Priority to JP2023189549A priority Critical patent/JP2024012211A/ja
Withdrawn legal-status Critical Current

Links

JP2019529625A 2016-12-16 2017-12-15 ミカファンギン組成物 Withdrawn JP2020510619A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023189549A JP2024012211A (ja) 2016-12-16 2023-11-06 ミカファンギン組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662435695P 2016-12-16 2016-12-16
US62/435,695 2016-12-16
PCT/US2017/066652 WO2018112330A1 (en) 2016-12-16 2017-12-15 Micafungin compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023189549A Division JP2024012211A (ja) 2016-12-16 2023-11-06 ミカファンギン組成物

Publications (2)

Publication Number Publication Date
JP2020510619A JP2020510619A (ja) 2020-04-09
JP2020510619A5 true JP2020510619A5 (enExample) 2021-01-28

Family

ID=60972375

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019529625A Withdrawn JP2020510619A (ja) 2016-12-16 2017-12-15 ミカファンギン組成物
JP2023189549A Pending JP2024012211A (ja) 2016-12-16 2023-11-06 ミカファンギン組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023189549A Pending JP2024012211A (ja) 2016-12-16 2023-11-06 ミカファンギン組成物

Country Status (11)

Country Link
US (2) US12403173B2 (enExample)
EP (1) EP3554474B1 (enExample)
JP (2) JP2020510619A (enExample)
AU (1) AU2017376960B2 (enExample)
DK (1) DK3554474T3 (enExample)
ES (1) ES2972008T3 (enExample)
FI (1) FI3554474T3 (enExample)
HU (1) HUE066069T2 (enExample)
PL (1) PL3554474T3 (enExample)
PT (1) PT3554474T (enExample)
WO (1) WO2018112330A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111044636A (zh) * 2019-12-30 2020-04-21 卓和药业集团有限公司 米卡芬净含量的分析方法
US20220040092A1 (en) * 2020-06-27 2022-02-10 RK Pharma Solutions LLC Ready to use injectable formulations of Micafungin Sodium
CN112710753A (zh) * 2020-12-18 2021-04-27 卓和药业集团有限公司 米卡芬净有关物质的分析方法
WO2024233925A1 (en) * 2023-05-11 2024-11-14 Hikma Pharmaceuticals Usa Inc. Stable micafungin compositions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849843A (en) 1993-11-16 1998-12-15 Baxter International Inc. Polymeric compositions for medical packaging and devices
US5998019A (en) 1993-11-16 1999-12-07 Baxter International Inc. Multi-layered polymer structure for medical products
MX9702531A (es) 1994-10-07 1997-06-28 Fujisawa Pharmaceutical Co Compuesto nuevo.
TWI233805B (en) 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
EP1193261A1 (en) 2000-10-02 2002-04-03 Warner-Lambert Company New thiadiazoles and their use as phosphodiesterase-7 inhibitors
US6991800B2 (en) * 2002-06-13 2006-01-31 Vicuron Pharmaceuticals Inc. Antifungal parenteral products
CN103360486A (zh) 2004-08-18 2013-10-23 诺瓦生命科学有限公司 包含含有精氨酸和/或赖氨酸的基序的抗微生物肽
WO2008137128A2 (en) 2007-05-03 2008-11-13 Northeastern University Methods of treating fungal infections
AU2013254940A1 (en) 2008-04-21 2014-01-16 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
MX2010012451A (es) 2008-05-15 2010-12-07 Baxter Int Formulaciones farmaceuticas estables.
GB0817121D0 (en) 2008-09-18 2008-10-29 Univ St Andrews Anti-fungal therapy
WO2010110686A1 (en) 2009-03-27 2010-09-30 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
US20110071072A1 (en) * 2009-08-28 2011-03-24 Georgetown University, A Congressionally Chartered Institution Of Higher Education Antifungal Bone Cements
CN102614492B (zh) * 2011-01-31 2013-12-11 上海天伟生物制药有限公司 一种含有棘白菌素类抗真菌剂米卡芬净的液体药用组合物
CN102775476B (zh) * 2011-05-12 2015-01-07 上海天伟生物制药有限公司 一种米卡芬净钠盐的制备方法
CN102512379B (zh) * 2011-12-16 2017-03-08 深圳市健元医药科技有限公司 一种新型棘白菌素类抗真菌药物组合物及其制备方法
SI3677252T1 (sl) 2012-03-19 2024-02-29 Cidara Therapeutics, Inc. Sheme odmerjanja za spojine iz razreda ehinokandinov
DK3240529T3 (da) * 2014-12-31 2022-02-28 Galenicum Health S L U Stabile farmaceutiske sammensætninger omfattende micafungin
CN108290845B (zh) * 2015-10-07 2021-08-03 大日本住友制药株式会社 嘧啶化合物
IN2015MU03858A (enExample) * 2015-10-10 2015-10-23 Gufic Biosciences Ltd

Similar Documents

Publication Publication Date Title
JP2020510619A5 (enExample)
JP2015527402A5 (enExample)
HRP20110801T1 (hr) Tekući oblik fsh
PH12017500844A1 (en) Stable protein solution formulation containing high concentration of an anti-vegf antibody
JP2013511522A5 (enExample)
US8431539B2 (en) Formulations of daptomycin
EA201492021A1 (ru) Антительный состав
JP2019529457A5 (enExample)
ES2875307T3 (es) Composición farmacéutica que contiene un compuesto derivado del ácido piridilaminoacético
JP2018502910A5 (enExample)
UA109421C2 (uk) Фармацевтична композиція, яка містить ліганди сигма-рецептора
HRP20240004T1 (hr) Formulacije agonista guanilat ciklaze c i postupci uporabe
HRP20250382T1 (hr) Farmaceutski pripravak koji sadrži karbetocin
JP2014530801A5 (enExample)
JP2016503058A5 (enExample)
RU2017103632A (ru) Суспензионные составы циклоспорина а для субконъюнктивального и периокулярного введения
RU2012134065A (ru) Альфа-2 адренергический агонист, обладающий эффектом длительного снижения внутриглазного давления
JP2019533679A5 (enExample)
AR093297A1 (es) Formulacion liquida que comprende un compuesto neutralizante de gm-csf
JP2013518051A5 (enExample)
ZA202102986B (en) Protein solution formulation containing high concentration of an anti-vegf antibody
HRP20110162A8 (hr) Spojevi koji sadrže amlodipin i bisoprolol
FI3554474T3 (fi) Mikafungiinikoostumuksia
JP2018188399A (ja) テリパラチドのプレフィルドシリンジ製剤
AR085273A1 (es) Formulacion liquida libre de propelente que comprende una droga antimuscarinica